JP2003506414A5 - - Google Patents

Download PDF

Info

Publication number
JP2003506414A5
JP2003506414A5 JP2001514977A JP2001514977A JP2003506414A5 JP 2003506414 A5 JP2003506414 A5 JP 2003506414A5 JP 2001514977 A JP2001514977 A JP 2001514977A JP 2001514977 A JP2001514977 A JP 2001514977A JP 2003506414 A5 JP2003506414 A5 JP 2003506414A5
Authority
JP
Japan
Prior art keywords
antibody
stated
pharmaceutical composition
bone marrow
nhl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001514977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003506414A (ja
JP4662672B2 (ja
Filing date
Publication date
Priority claimed from US09/625,856 external-priority patent/US6451284B1/en
Application filed filed Critical
Publication of JP2003506414A publication Critical patent/JP2003506414A/ja
Publication of JP2003506414A5 publication Critical patent/JP2003506414A5/ja
Application granted granted Critical
Publication of JP4662672B2 publication Critical patent/JP4662672B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001514977A 1999-08-11 2000-07-31 放射性免疫療法に先立つ血液学的毒性測定のための新規な臨床検査指標 Expired - Lifetime JP4662672B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14828899P 1999-08-11 1999-08-11
US60/148,288 1999-08-11
US09/625,856 US6451284B1 (en) 1999-08-11 2000-07-26 Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US09/625,856 2000-07-26
PCT/US2000/020733 WO2001010461A1 (en) 1999-08-11 2000-07-31 New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy

Publications (3)

Publication Number Publication Date
JP2003506414A JP2003506414A (ja) 2003-02-18
JP2003506414A5 true JP2003506414A5 (cg-RX-API-DMAC7.html) 2007-10-04
JP4662672B2 JP4662672B2 (ja) 2011-03-30

Family

ID=26845721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001514977A Expired - Lifetime JP4662672B2 (ja) 1999-08-11 2000-07-31 放射性免疫療法に先立つ血液学的毒性測定のための新規な臨床検査指標

Country Status (17)

Country Link
US (3) US6451284B1 (cg-RX-API-DMAC7.html)
EP (1) EP1207904B1 (cg-RX-API-DMAC7.html)
JP (1) JP4662672B2 (cg-RX-API-DMAC7.html)
CN (2) CN100540053C (cg-RX-API-DMAC7.html)
AT (1) ATE387915T1 (cg-RX-API-DMAC7.html)
AU (2) AU780222B2 (cg-RX-API-DMAC7.html)
CA (1) CA2378584C (cg-RX-API-DMAC7.html)
CY (1) CY1108118T1 (cg-RX-API-DMAC7.html)
DE (1) DE60038239T2 (cg-RX-API-DMAC7.html)
DK (1) DK1207904T3 (cg-RX-API-DMAC7.html)
ES (1) ES2302698T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA02001403A (cg-RX-API-DMAC7.html)
MY (1) MY135734A (cg-RX-API-DMAC7.html)
NO (1) NO329592B1 (cg-RX-API-DMAC7.html)
PT (1) PT1207904E (cg-RX-API-DMAC7.html)
TW (1) TWI317284B (cg-RX-API-DMAC7.html)
WO (1) WO2001010461A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
WO2001010462A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
AU6836301A (en) * 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック, インコーポレイテッド 併用療法
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Cd20-특이적 항체 및 이를 이용한 방법
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
CA2572451C (en) 2004-06-02 2016-05-10 Sidney Kimmel Cancer Center Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
SG183012A1 (en) 2004-06-04 2012-08-30 Genentech Inc Method for treating multiple sclerosis
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2586788B1 (en) 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
WO2015089632A1 (en) 2013-12-17 2015-06-25 Alentic Microscience Inc. Dosimeters including lensless imaging systems
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
EP3714937A1 (en) * 2019-03-28 2020-09-30 Koninklijke Philips N.V. Determining hematologic toxicity risk following radiotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
CA2095141A1 (en) 1990-11-05 1992-05-06 Ingegerd Hellstrom Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ATE139900T1 (de) * 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5843436A (en) * 1996-04-22 1998-12-01 The Trustees Of Columbia University, In The City Of New York Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination

Similar Documents

Publication Publication Date Title
DE60038239T2 (de) Neue klinische parameter zur bestimmung einer hämatologischen toxizität vor einer strahlenimmuntherapie
Davis et al. The radioisotope contributes significantly to the activity of radioimmunotherapy
Lindén et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
JP2003513012A5 (cg-RX-API-DMAC7.html)
Burke et al. Radioimmunotherapy for acute leukemia
JP2003506413A (ja) 中間および高グレードの非ホジキンリンパ腫の抗−cd20抗体による治療
JP2004512262A5 (cg-RX-API-DMAC7.html)
AU7626000A (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
Tuscano et al. Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
Jurcic Targeted alpha-particle therapy for hematologic malignancies
Witzig Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin’s lymphoma
Borghaei et al. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
Iagaru et al. 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) therapy of low-grade refractory/relapsed Non-Hodgkin Lymphoma
Illidge et al. Radioimmunotherapy in follicular lymphoma
Michel et al. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo
Torres-García et al. Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience
Emmanouilides Radioimmunotherapy for non-Hodgkin’s lymphoma
Leonard et al. Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma: HEMATOLOGY
William et al. I-131 tositumomab
White Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin®).
Bailly et al. Radioimmunotherapy of lymphomas
Meredith et al. Clinical development of radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
Jurcic Targeted alpha-particle immunotherapy with bismuth-213 and actinium-225 for acute myeloid leukemia
Emmanouilides Radioimmunotherapy for Waldenstrom's macroglobulinemia
Grillo-López 90Y-ibritumomab tiuxetan: Rationale for patient selection in the treatment of indolent non-Hodgkin’s lymphoma